Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors

Thierry Delaunoit, Joseph Rubin, Florence Neczyporenko, Charles Erlichman, Timothy James Hobday

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Gastroenteropancreatic neuroendocrine tumors constitute a heterogeneous group of neoplasms that are often associated with typical symptoms due to excessive and uncontrolled release of diverse hormones. Because these tumors are usually slow growing, surgery is the cornerstone of treatment. However, these rare tumors can present with rapid progression that requires aggressive systemic therapy or diffuse metastatic disease net amenable to surgical palliation. For most patients, medical approaches are necessary at some point in the course of their disease, especially since most tumors are at an advanced stage at the time of diagnosis. Most gastroenteropancreatic neuroendocrine tumors express high levels of somatostatin receptors, which are bound by somatostatin or its synthetic analogues. These agents, alone or combined with other therapies, such as interferon or radioisotopes, are therefore used frequently to control hormone-related symptoms and, for some patients, the growth of the disease itself. This article reviews the evidence for the use of somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors based on a MEDLINE search of literature published from January 1970 to July 2003.

Original languageEnglish (US)
Pages (from-to)502-506
Number of pages5
JournalMayo Clinic Proceedings
Volume80
Issue number4
StatePublished - 2005

Fingerprint

Somatostatin
Neoplasms
Hormones
Somatostatin Receptors
Therapeutics
MEDLINE
Radioisotopes
Interferons
Gastro-enteropancreatic neuroendocrine tumor
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Delaunoit, T., Rubin, J., Neczyporenko, F., Erlichman, C., & Hobday, T. J. (2005). Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clinic Proceedings, 80(4), 502-506.

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. / Delaunoit, Thierry; Rubin, Joseph; Neczyporenko, Florence; Erlichman, Charles; Hobday, Timothy James.

In: Mayo Clinic Proceedings, Vol. 80, No. 4, 2005, p. 502-506.

Research output: Contribution to journalArticle

Delaunoit, T, Rubin, J, Neczyporenko, F, Erlichman, C & Hobday, TJ 2005, 'Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors', Mayo Clinic Proceedings, vol. 80, no. 4, pp. 502-506.
Delaunoit, Thierry ; Rubin, Joseph ; Neczyporenko, Florence ; Erlichman, Charles ; Hobday, Timothy James. / Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. In: Mayo Clinic Proceedings. 2005 ; Vol. 80, No. 4. pp. 502-506.
@article{fc21aface33a43cb85f3f5e6992a3b29,
title = "Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors",
abstract = "Gastroenteropancreatic neuroendocrine tumors constitute a heterogeneous group of neoplasms that are often associated with typical symptoms due to excessive and uncontrolled release of diverse hormones. Because these tumors are usually slow growing, surgery is the cornerstone of treatment. However, these rare tumors can present with rapid progression that requires aggressive systemic therapy or diffuse metastatic disease net amenable to surgical palliation. For most patients, medical approaches are necessary at some point in the course of their disease, especially since most tumors are at an advanced stage at the time of diagnosis. Most gastroenteropancreatic neuroendocrine tumors express high levels of somatostatin receptors, which are bound by somatostatin or its synthetic analogues. These agents, alone or combined with other therapies, such as interferon or radioisotopes, are therefore used frequently to control hormone-related symptoms and, for some patients, the growth of the disease itself. This article reviews the evidence for the use of somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors based on a MEDLINE search of literature published from January 1970 to July 2003.",
author = "Thierry Delaunoit and Joseph Rubin and Florence Neczyporenko and Charles Erlichman and Hobday, {Timothy James}",
year = "2005",
language = "English (US)",
volume = "80",
pages = "502--506",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors

AU - Delaunoit, Thierry

AU - Rubin, Joseph

AU - Neczyporenko, Florence

AU - Erlichman, Charles

AU - Hobday, Timothy James

PY - 2005

Y1 - 2005

N2 - Gastroenteropancreatic neuroendocrine tumors constitute a heterogeneous group of neoplasms that are often associated with typical symptoms due to excessive and uncontrolled release of diverse hormones. Because these tumors are usually slow growing, surgery is the cornerstone of treatment. However, these rare tumors can present with rapid progression that requires aggressive systemic therapy or diffuse metastatic disease net amenable to surgical palliation. For most patients, medical approaches are necessary at some point in the course of their disease, especially since most tumors are at an advanced stage at the time of diagnosis. Most gastroenteropancreatic neuroendocrine tumors express high levels of somatostatin receptors, which are bound by somatostatin or its synthetic analogues. These agents, alone or combined with other therapies, such as interferon or radioisotopes, are therefore used frequently to control hormone-related symptoms and, for some patients, the growth of the disease itself. This article reviews the evidence for the use of somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors based on a MEDLINE search of literature published from January 1970 to July 2003.

AB - Gastroenteropancreatic neuroendocrine tumors constitute a heterogeneous group of neoplasms that are often associated with typical symptoms due to excessive and uncontrolled release of diverse hormones. Because these tumors are usually slow growing, surgery is the cornerstone of treatment. However, these rare tumors can present with rapid progression that requires aggressive systemic therapy or diffuse metastatic disease net amenable to surgical palliation. For most patients, medical approaches are necessary at some point in the course of their disease, especially since most tumors are at an advanced stage at the time of diagnosis. Most gastroenteropancreatic neuroendocrine tumors express high levels of somatostatin receptors, which are bound by somatostatin or its synthetic analogues. These agents, alone or combined with other therapies, such as interferon or radioisotopes, are therefore used frequently to control hormone-related symptoms and, for some patients, the growth of the disease itself. This article reviews the evidence for the use of somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors based on a MEDLINE search of literature published from January 1970 to July 2003.

UR - http://www.scopus.com/inward/record.url?scp=16344392964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344392964&partnerID=8YFLogxK

M3 - Article

C2 - 15819288

AN - SCOPUS:16344392964

VL - 80

SP - 502

EP - 506

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -